Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Profound Medical (PROF) Research & Development (2019 - 2026)

Profound Medical has reported Research & Development over the past 7 years, most recently at $4.3 million for Q4 2025.

  • For Q4 2025, Research & Development fell 8.11% year-over-year to $4.3 million; the TTM value through Dec 2025 reached $20.6 million, up 21.4%, while the annual FY2025 figure was $20.6 million, 21.4% up from the prior year.
  • Research & Development for Q4 2025 was $4.3 million at Profound Medical, down from $5.4 million in the prior quarter.
  • Over five years, Research & Development peaked at $6.1 million in Q2 2025 and troughed at $3.1 million in Q4 2022.
  • A 5-year average of $4.1 million and a median of $4.0 million in 2021 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: skyrocketed 98.66% in 2021 and later crashed 34.26% in 2022.
  • Year by year, Research & Development stood at $4.7 million in 2021, then tumbled by 34.26% to $3.1 million in 2022, then grew by 29.94% to $4.0 million in 2023, then grew by 15.82% to $4.6 million in 2024, then decreased by 8.11% to $4.3 million in 2025.
  • Business Quant data shows Research & Development for PROF at $4.3 million in Q4 2025, $5.4 million in Q3 2025, and $6.1 million in Q2 2025.